Colorectal cancer

被引:4511
作者
Dekker, Evelien [1 ]
Tanis, Pieter J. [2 ]
Vleugels, Jasper L. A. [1 ,3 ]
Kasi, Pashtoon M. [4 ]
Wallace, Michael B. [5 ]
机构
[1] Amsterdam Univ Med Ctr, Locat Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands
[2] Amsterdam Univ Med Ctr, Locat Acad Med Ctr, Dept Surg, Amsterdam, Netherlands
[3] Amsterdam Univ Med Ctr, Locat Acad Med Ctr, Dept Internal Med, Amsterdam, Netherlands
[4] Univ Iowa, Dept Med Oncol, Iowa City, IA USA
[5] Mayo Clin, Dept Gastroenterol & Hepatol, Jacksonville, FL 32224 USA
关键词
III COLON-CANCER; ENDOSCOPIC MUCOSAL RESECTION; OXALIPLATIN-BASED CHEMOTHERAPY; EGFR MONOCLONAL-ANTIBODIES; LONG-TERM OUTCOMES; RECTAL-CANCER; ADJUVANT TREATMENT; 1ST-LINE TREATMENT; MISMATCH-REPAIR; OPEN-LABEL;
D O I
10.1016/S0140-6736(19)32319-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several decades ago, colorectal cancer was infrequently diagnosed. Nowadays, it is the world's fourth most deadly cancer with almost 900 000 deaths annually. Besides an ageing population and dietary habits of high-income countries, unfavourable risk factors such as obesity, lack of physical exercise, and smoking increase the risk of colorectal cancer. Advancements in pathophysiological understanding have increased the array of treatment options for local and advanced disease leading to individual treatment plans. Treatments include endoscopic and surgical local excision, downstaging preoperative radiotherapy and systemic therapy, extensive surgery for locoregional and metastatic disease, local ablative therapies for metastases, and palliative chemotherapy, targeted therapy, and immunotherapy. Although these new treatment options have doubled overall survival for advanced disease to 3 years, survival is still best for those with non-metastasised disease. As the disease only becomes symptomatic at an advanced stage, worldwide organised screening programmes are being implemented, which aim to increase early detection and reduce morbidity and mortality from colorectal cancer.
引用
收藏
页码:1467 / 1480
页数:14
相关论文
共 165 条
[1]   Integrating Systemic Therapies into the Multimodality Treatment of Resectable Colorectal Liver Metastases [J].
Abdel-Rahman, Omar ;
Cheung, Winson Y. .
GASTROENTEROLOGY RESEARCH AND PRACTICE, 2018, 2018
[2]   Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program [J].
Adenis, Antoine ;
de la Fouchardiere, Christelle ;
Paule, Bernard ;
Burtin, Pascal ;
Tougeron, David ;
Wallet, Jennifer ;
Dourthe, Louis-Marie ;
Etienne, Pierre-Luc ;
Mineur, Laurent ;
Clisant, Stephanie ;
Phelip, Jean-Marc ;
Kramar, Andrew ;
Andre, Thierry .
BMC CANCER, 2016, 16
[3]   Actual endoscopic versus predicted surgical mortality for treatment of advanced mucosal neoplasia of the colon [J].
Ahlenstiel, Golo ;
Hourigan, Luke F. ;
Brown, Gregor ;
Zanati, Simon ;
Williams, Stephen J. ;
Singh, Rajvinder ;
Moss, Alan ;
Sonson, Rebecca ;
Bourke, Michael J. .
GASTROINTESTINAL ENDOSCOPY, 2014, 80 (04) :668-676
[4]   Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer A Randomized Trial [J].
Alberts, Steven R. ;
Sargent, Daniel J. ;
Nair, Suresh ;
Mahoney, Michelle R. ;
Mooney, Margaret ;
Thibodeau, Stephen N. ;
Smyrk, Thomas C. ;
Sinicrope, Frank A. ;
Chan, Emily ;
Gill, Sharlene ;
Kahlenberg, Morton S. ;
Shields, Anthony F. ;
Quesenberry, James T. ;
Webb, Thomas A. ;
Farr, Gist H., Jr. ;
Pockaj, Barbara A. ;
Grothey, Axel ;
Goldberg, Richard M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (13) :1383-1393
[5]   Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials [J].
Algra, Annemijn M. ;
Rothwell, Peter M. .
LANCET ONCOLOGY, 2012, 13 (05) :518-527
[6]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[7]   Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].
Andre, Thierry ;
Boni, Corrado ;
Navarro, Matilde ;
Tabernero, Josep ;
Hickish, Tamas ;
Topham, Clare ;
Bonetti, Andrea ;
Clingan, Philip ;
Bridgewater, John ;
Rivera, Fernando ;
de Gramont, Aimery .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116
[8]  
[Anonymous], IARC CANC TODAY
[9]  
[Anonymous], 2017, J NATL CANC I
[10]  
[Anonymous], 2017, J CLIN ONCOL